Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With most brokers taking a break over the holiday period, research notes are few and far between right now.

But don't worry! Listed below are three recent broker buy recommendations that still have plenty of upside potential.

Here's why brokers think these ASX shares are in the buy zone:

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.

Image source: Getty Images

Pilbara Minerals Ltd (ASX: PLS)

According to a note from Bell Potter, its analysts upgraded this lithium miner's shares to a buy rating with a $2.95 price target.

The broker made the move for a couple of key reasons. The first was on valuation grounds believing that a sharp pullback in its share price has created a buying opportunity for investors. Especially now that short interest in the lithium miner is falling.

Another key reason to invest, according to Bell Potter, is the improving outlook for lithium. Its analysts believe that there could be lithium supply deficits from 2026, which would be a huge boost to prices.

And with Pilbara Minerals having a very strong balance sheet, Bell Potter feels that it is well-placed to respond. The Pilbara Minerals share price is trading at $2.24 this morning.

Pro Medicus Limited (ASX: PME)

A note from Goldman Sachs revealed that its analysts retained their buy rating on this health imaging technology company's shares with an improved price target of $278.00.

The broker believes that Pro Medicus is one of Australia's best global growth companies. This is based partly on its belief that further Visage 7 adoption is a matter of when not if. Goldman is forecasting a strong increase in the value and cadence of contract wins over time.

And while it acknowledges that Pro Medicus' shares are not cheap, trading on 114x FY26E EV/EBITDA, the broker feels that this premium is justified due to its revenue/margin outlook, unique cloud offering, and significant long-term opportunity. The Pro Medicus share price is fetching $250.14 on Friday.

Super Retail Group Ltd (ASX: SUL)

Analysts at Morgans retained their add rating on this retail group's shares with a trimmed price target of $18.55. This followed the release of a first-quarter update from the BCF, Rebel, Macpac, and Supercheap Auto owner.

Morgans notes that the update was a touch softer than expected. This has led to its analysts trimming their earnings forecasts to reflect the challenging trading conditions in the auto parts industry.

Nevertheless, the broker remains positive on its outlook and sees plenty of value on offer with its shares. In addition, Morgans expects Super Retail's shares to offer 6%+ fully franked dividend yields in the near term. The Super Retail share price is trading at $15.34 today.

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Super Retail Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Super Retail Group. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

A smiling woman at a hardware shop selects paint colours from a wall display.
Broker Notes

Wesfarmers shares: Buy, hold or sell?

A leading analyst delivers his verdict on Wesfarmers shares.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Broker Notes

Buy, hold, sell: Cochlear, CSL, and DroneShield shares

Are these hugely popular shares in the buy zone or not? Let's find out.

Read more »

Man with rocket wings which have flames coming out of them.
Broker Notes

These ASX 200 shares could rise ~40% to 80%

Brokers are predicting big returns for these top shares. Here's what you need to know.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Broker Notes

2 ASX 200 stocks that could rise 50%

Morgans thinks the market is undervaluing these shares.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Dollar sign in yellow with a red falling arrow in front of a graph, symbolising a falling share price.
Broker Notes

6 ASX 200 shares downgraded by brokers this week

Brokers have reduced their ratings on TechnologyOne, Macquarie, 4DMedical, and others this week.

Read more »